Should a 67-year-old woman who is taking rosuvastatin (Crestor) start daily low-dose aspirin 81 mg?

Should a 67-Year-Old Woman Taking Crestor Start Daily 81 mg Aspirin?

The decision depends critically on her cardiovascular risk profile and bleeding risk, but for most 67-year-old women, aspirin is NOT recommended for primary prevention based on the most recent evidence.

Current Evidence-Based Recommendations

The 2022 USPSTF guidelines represent the most recent high-quality evidence and recommend against initiating aspirin for primary prevention in adults 60 years or older (Grade D recommendation) 1. This is a significant departure from older guidelines and reflects updated evidence showing no net benefit in this age group 1, 2.

Key Considerations for This Patient

Age-specific factors:

• At 67 years old, this patient falls into the age category where the 2022 USPSTF explicitly recommends against initiating aspirin for primary prevention 1
• Older adults (≥60 years) have increased bleeding risk that outweighs potential cardiovascular benefits 1, 3
• Studies show that 45.3% of adults aged ≥75 inappropriately take aspirin for primary prevention despite lack of benefit 4

The fact she takes Crestor (rosuvastatin) indicates:

• She likely has hyperlipidemia or elevated cardiovascular risk 5
• Statin therapy alone is appropriate for lipid management 5
• There is no drug interaction between aspirin and rosuvastatin requiring special consideration 5

Decision Algorithm

Step 1: Determine if this is PRIMARY or SECONDARY prevention

Does she have established cardiovascular disease?

• Prior myocardial infarction
• Prior stroke or TIA
• Coronary artery disease with prior stenting/CABG
• Peripheral arterial disease
• Documented coronary stenosis

If YES → This is SECONDARY prevention:

• Aspirin 81 mg daily IS recommended 6
• Continue indefinitely unless contraindicated 6

If NO → This is PRIMARY prevention:

• Proceed to Step 2

Step 2: Assess bleeding risk

High bleeding risk factors include:

• History of gastrointestinal bleeding or ulcers 7, 1
• Concurrent anticoagulation therapy 8
• Uncontrolled hypertension 7
• Thrombocytopenia or bleeding disorders 1
• Chronic kidney disease 5
• Age ≥65 years (inherent increased risk) 7, 3

If high bleeding risk → DO NOT start aspirin 1

Step 3: For primary prevention without high bleeding risk

Based on 2022 USPSTF (most recent guideline):

• Age ≥60 years: DO NOT initiate aspirin (Grade D) 1, 2
• The net benefit is absent due to increased bleeding risk offsetting any cardiovascular benefit 1

Older 2011 AHA/ASA guidelines (now superseded) suggested aspirin could be considered in women >65 years with:

• Controlled blood pressure AND
• 10-year cardiovascular risk ≥10% AND
• Benefits likely outweigh bleeding risks 7

However, the 2022 USPSTF evidence supersedes these older recommendations 1.

Bleeding Risk Data

In women taking aspirin for primary prevention:

• Gastrointestinal bleeding requiring transfusion: 0.06% per year (vs 0.05% placebo) 7
• Number needed to harm: 10,000 per year 7
• Risk increases significantly in adults ≥70 years 9
• In healthy elderly (≥70 years), aspirin caused 3% clinically evident GI bleeding over 12 months vs 0% with placebo 3
• Mean hemoglobin decreased significantly more with aspirin (0.33 g/dL vs 0.11 g/dL placebo) 3

Special Populations Where Aspirin May Be Considered

The 2011 AHA/ASA guidelines (older but still referenced) noted aspirin showed benefit in women ≥65 years with specific risk factors:

• Hypertension (RR 0.76 for stroke) 7
• Hyperlipidemia (RR 0.62 for stroke) 7
• Diabetes (RR 0.46 for stroke) 7
• 10-year cardiovascular risk ≥10% (RR 0.54) 7

However, these benefits must be weighed against:

• Increased hemorrhagic stroke risk 7
• Increased GI bleeding 7
• The 2022 USPSTF recommendation against use in this age group 1

Important Caveats

Aspirin is NOT recommended for primary prevention in:

• Low-risk individuals (Class III) 7
• Patients with diabetes alone without established CVD (Class III) 7
• Adults ≥60 years per 2022 USPSTF 1

Common pitfall: Many older adults continue taking aspirin for primary prevention despite lack of evidence and increased bleeding risk 4. This represents inappropriate prescribing that should be addressed.

Drug interaction note: While Crestor has no direct interaction with aspirin, patients on statins who develop muscle symptoms should be monitored carefully, as both medications can rarely cause muscle problems 5.

Bottom Line Recommendation

For a 67-year-old woman taking Crestor WITHOUT established cardiovascular disease: DO NOT start aspirin for primary prevention 1, 2. The 2022 USPSTF Grade D recommendation explicitly advises against this practice in adults ≥60 years.

If she has established cardiovascular disease (prior MI, stroke, known CAD): START aspirin 81 mg daily 6 and continue indefinitely unless bleeding complications occur.

The presence of hyperlipidemia (reason for Crestor) alone does not justify aspirin in the absence of established atherosclerotic disease, despite older guidelines suggesting potential benefit 7, 1.